

Day 1
KidneyGenAfrica Workshop

Case Study

Robert Kalyesubula
June Fabian



Learning Objectives: CKD-u

You will:

Gain an overview of how disease definitions for chronic kidney disease were derived

Explore what is known about the causation of chronic kidney disease

Consider the ethical and practical challenges of investigating a subclinical disease

Receive an introduction to ongoing research regarding chronic kidney disease of unknown origin

Consider benefits and disadvantages of different epidemiological study designs in studying a subclinical condition



Learning Objectives: CKD-u

Current definitions used in clinical care for chronic kidney disease are driven by risk analyses of biomarker measurements.

A small subset of people with very advanced kidney disease or rapidly progressing primary kidney disease will end up on dialysis.

Most people who are detected with these biomarkers are asymptomatic, and/or attribute their health problems to other conditions (e.g. diabetes, cardiovascular disease, heart failure, hypertension).



Non-invasive Biomarkers for CKD

Damage to the tubule


urinary markers for research purposes only, not in routine use.

Damage to the glomerulus


Albuminuria/proteinuria (“leaking sieve”)

Glomerular filtration rate (GFR)

estimated GFR, based on measured serum creatinine and/or measured serum cystatin C



CKD and mortality



CKD and KDIGO

Prognosis of CKD and by eGFR and Albuminuria Categories: KDIGO 2012				Persistent albuminuria categories Urine ACR (mg/mmol) Description and range		
				A1	A2	A3
				Normal male < 2.5 female < 3.5	Microalbuminuria male 2.5 – 25 female 3.5 – 35	Macroalbuminuria male > 25 female > 35
eGFR categories (mL/min/1.73m ²) Description and range	G1	Normal or high	>90			
	G2	Mildly decreased	60–89			
	G3a	Mildly to moderately decreased	45–59			
	G3b	Moderately to severely decreased	30–44			
	G4	Severely decreased	15–29			
	G5	Kidney failure	<15			

■ low risk if no other markers of kidney disease, no CKD)
 ■ Moderately increased risk
 ■ high risk
 ■ very high risk



Breakout 1

Consider the paper on 'An update on the global disparities in kidney disease burden and care across countries and regions' ([https://doi.org/10.1016/s2214-109x\(23\)00570-3](https://doi.org/10.1016/s2214-109x(23)00570-3))

Questions to discuss in Breakout groups

- What are the risks and benefits of screening for kidney disease in settings where access to chronic dialysis and transplantation are severely restricted?
- How would you plan the implementation of public health screening to identify individuals with eGFR < 60 or albuminuria in a resource-limited setting?
- Specifically discuss:
 - Informed consent
 - Duty of care
 - Risk vs benefit of point-of-care devices vs designated pathology laboratories



CKD-u: Central America

A dramatic increase of chronic kidney disease of unknown origin (CKDu)

Unexplained by conventional risk factors such as hypertension and diabetes

Primarily affecting adult male agricultural workers, in particular sugarcane workers

Nicaragua 2002-2012:

- 46% of all male deaths were due to CKD
- 75% of deaths of men aged 35 to 55 were due to CKD.
- Mortality rate due to CKD doubled




Challenges of estimating prevalence of CKDu

- CKDu clinically silent until it has progressed to advanced stage, so need to test asymptomatic patients to include initial stages of disease
- Lack of reliable registries for CKDu:
 - Definition of CKDu in mortality records may vary according to awareness of CKDu in the area
 - Dialysis or transplant registries not available in all regions
- No clear clinical definition of CKDu:
 - Distribution of glomerular filtration rate (GFR) may vary between regions
 - Estimates of GFR (eGFR) are affected by ethnicity and body composition




Prospective cohort study of a young population




Even after excluding those with self-reported CKD, 9.5% of the apparently healthy men (but no women) in the study had evidence of baseline renal dysfunction.

ME
N



Rapid loss of eGFR from normal baseline levels was found in 9.5% of men and 3.4% of women.

WOME
N



Among men, risk factors at baseline for rapid decline included working outdoors, agricultural work, and lack of shade availability

? Occupational or Environmental ?

Balkans (1920) - “Balkan Nephropathy” from aristolochic acid in wheat


Japan (1910 – 1960) – “Itai Itai Disease” from cadmium in waste water

Japan – “Mercury Nephropathy” from eating fish contaminated with organic mercury

Tunisia – CKDu from a mycotoxin contaminant in food (Ochratoxin)



International prevalence patterns of low eGFR in adults aged 18-60 without traditional risk factors from a population-based cross-sectional disadvantaged populations eGFR epidemiology (DEGREE) study



OPEN

Charlotte E. Rutter¹, Mary Njoroge¹, Philip J. Cooper^{2,3}, Dorairaj Prabhakaran⁴, Vivekanand Jha^{5,6,7}, Prabhdeep Kaur⁸, Sailesh Mohan⁴, Ravi Raju Tatapudi⁹, Annibale Biggeri¹⁰, Peter Rohloff¹¹, Michelle H. Hathaway¹², Amelia C. Crampin^{13,14}, Meghnath Dhimal¹⁵, Anil Poudyal¹⁵, Antonio Bernabe-Ortiz¹⁶, Cristina O'Callaghan-Gordo^{17,18,19,20}, Pubudu Chulasiri²¹, Nalika Gunawardena²², Thilanga Ruwanpathirana²³, S.C. Wickramasinghe²⁴, Sameera Senanayake²⁵, Chagriya Kitiyakara²⁶, Marvin Gonzalez-Quiroz^{27,28,29}, Sandra Cortés³⁰, Kristina Jakobsson^{31,32}, Ricardo Correa-Rotter^{33,34}, Jason Glaser³², Ajay Singh³⁵, Sophie Hamilton³⁶, Devaki Nair^{28,37,38}, Aurora Aragón²⁹, Dorothea Nitsch³⁹, Steven Robertson⁴⁰, Ben Caplin²⁸ and Neil Pearce¹; and the DEGREE Study Group⁴¹




Figure 1 | Age-standardized prevalence of creatinine-based estimated glomerular filtration rate (eGFR) <60 ml/min per 1.73 m² in rural^a men without hypertension, diabetes, or heavy proteinuria. ^aUSA includes rural and urban together.

Breakout 2

Questions to discuss in Breakout groups

Why do you think CKD-u is a risk in African populations?

What studies would you design to determine the prevalence of CKD-u in African countries?

What studies would you design to understand what causes CKD-u in African countries?

- For each of these questions, please suggest a study design, target populations, baseline/follow-up assessments, duration, and size of study.

What would you advise your local Ministry of Health to do about CKD-u?

Each group should assign a colleague to provide feedback on the group's suggested answers.

